PEDF treatment by gene therapy or administration of recombinant protein was shown to inhibit the growth of pancreatic cancer [8], hepatoblastoma [6], prostate cancer [7], retinoblastoma [10], ocular melanoma [11], lung cancer and colon cancer [9]. This evidence concerns the gene SERPINF1 and lung carcinoma.